SI2139892T1 - Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji - Google Patents

Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji

Info

Publication number
SI2139892T1
SI2139892T1 SI200830445T SI200830445T SI2139892T1 SI 2139892 T1 SI2139892 T1 SI 2139892T1 SI 200830445 T SI200830445 T SI 200830445T SI 200830445 T SI200830445 T SI 200830445T SI 2139892 T1 SI2139892 T1 SI 2139892T1
Authority
SI
Slovenia
Prior art keywords
pyrimidodiazepines
substituted
useful
plk1 inhibitors
plk1
Prior art date
Application number
SI200830445T
Other languages
English (en)
Slovenian (sl)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takede Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2139892(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takede Pharmaceutical Company Ltd filed Critical Takede Pharmaceutical Company Ltd
Publication of SI2139892T1 publication Critical patent/SI2139892T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200830445T 2007-03-22 2008-03-11 Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji SI2139892T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
EP08717594A EP2139892B1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
SI2139892T1 true SI2139892T1 (sl) 2011-12-30

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830445T SI2139892T1 (sl) 2007-03-22 2008-03-11 Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN102746175B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190849B1 (en) * 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
EA026557B1 (ru) * 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6553589B2 (ja) 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
CN107074860B (zh) 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
AU2015318061B2 (en) 2014-09-16 2018-05-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
EP4034132A4 (en) * 2019-09-27 2023-10-11 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
CA3228601A1 (en) * 2021-08-10 2023-02-16 Soo Hee RYU Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7491400A (en) * 1999-09-17 2001-04-17 Abbott Gmbh & Co. Kg Kinase inhibitors as therapeutic agents
NZ531928A (en) 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
KR20080095902A (ko) * 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP2139892A1 (en) 2010-01-06
JP2010521514A (ja) 2010-06-24
CL2008000785A1 (es) 2009-03-27
KR101157848B1 (ko) 2012-07-11
HK1139936A1 (en) 2010-09-30
TWI363629B (en) 2012-05-11
IL200617A (en) 2014-02-27
CN101636399B (zh) 2012-04-18
US20080234255A1 (en) 2008-09-25
PE20120495A1 (es) 2012-05-12
MX2009010034A (es) 2009-10-12
WO2008113711A1 (en) 2008-09-25
CA2680757A1 (en) 2008-09-25
AR065794A1 (es) 2009-07-01
TW200843781A (en) 2008-11-16
EP2139892B1 (en) 2011-09-14
CY1112102T1 (el) 2015-11-04
AU2008228303B2 (en) 2012-04-19
ATE524472T1 (de) 2011-09-15
JP5087640B2 (ja) 2012-12-05
DK2139892T3 (da) 2011-12-12
BRPI0809088A2 (pt) 2014-09-09
PT2139892E (pt) 2011-11-21
CN102746175B (zh) 2014-01-15
AU2008228303A1 (en) 2008-09-25
US7517873B2 (en) 2009-04-14
KR20090119913A (ko) 2009-11-20
ES2371832T3 (es) 2012-01-10
IL200617A0 (en) 2010-05-17
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
PL2139892T3 (pl) 2012-03-30
HRP20110807T1 (hr) 2011-12-31

Similar Documents

Publication Publication Date Title
IL200617A0 (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
AP2010005163A0 (en) Substituted bicyclolactam compounds
IL198675A0 (en) Novel aminopyrimidine derivatives as plk1 inhibitors
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
ZA201100898B (en) Novel inhibitors
IL200153A0 (en) Novel phosphodiesterase inhibitors
ZA200905371B (en) Novel phosphodiesterase Inhibitors
ZA200905263B (en) Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
GB0714941D0 (en) Inhibitors
GB0701985D0 (en) Compounds
GB0701955D0 (en) Compounds
GB0707498D0 (en) Novel inhibitors
GB0707493D0 (en) Novel inhibitors
GB0707497D0 (en) Novel inhibitors
GB0707495D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors
GB0704589D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0720364D0 (en) Inhibitor
GB0816125D0 (en) Novel inhibitors
ZA200903127B (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
GB0701197D0 (en) Compounds